Implementation of gastric cancer screening - The global experience

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 6, 2014, Pages 1093-1106

  Leja, Marcis ^a   You, Weicheng ^b   Camargo, M Constanza ^c   Saito, Hiroshi ^d  

^a UNIVERSITY OF LATVIA   (Latvia)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

Biomarkers; Gastric cancer; Helicobacter pylori; Precancerous lesions; Screening

Indexed keywords

GASTRIN 17; GHRELIN; INTESTINAL TREFOIL FACTOR; PEPSINOGEN; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BACTERIAL CLEARANCE; BACTERIAL VIRULENCE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CHINA; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); ENDOSCOPIC SURGERY; ERADICATION THERAPY; EUROPE; FLUOROGRAPHY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL RADIOGRAPHY; HEALTH CARE PLANNING; HEALTH PROGRAM; HELICOBACTER PYLORI; HUMAN; JAPAN; KAZAKHSTAN; KOREA; MULTICENTER STUDY (TOPIC); NON INVASIVE PROCEDURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SOUTH AND CENTRAL AMERICA; STOMACH CANCER; WORK EXPERIENCE; X RAY; EARLY DIAGNOSIS; HEALTH; STOMACH NEOPLASMS;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; GLOBAL HEALTH; HUMANS; STOMACH NEOPLASMS;

EID: 84927959592     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.09.005     Document Type: Review

References (100)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: Http://globocan.iarc.fr [accessed 05.01.14].
2. Forman D, Sierra M.S. 2014. The current and projected global burden of gastric cancer, In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. IARC Helicobacter pyloriWorking Group. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), 5-15. Available from: Http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55: 74-108.
4. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCAREe5-A population-based study. Lancet Oncol 2014;15: 23-34.
5. Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: An updated analysis of 1992-2009 SEER data. Dig Dis Sci 2014. http://dx.doi.org/10.1007/s10620-014-3275-3 [in press].
6. Pasechnikov V, Chukov S, Fedorov J, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis.World J Gastroenterol 2014;20(38): 13842-62.
7. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44: 74-94.
8. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus report. Gut 2012;61: 646-64.
9. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: From biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013;27: 205-23.
10. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology 2008;134: 945-52.
11. IARC. Cervix cancer screening. IARC handbooks of cancer prevention, 10. Lyon: International Agency for Research on Cancer; 2005.
12. Nakajima T. Historical review of research and treatment of gastric cancer in Japan: Clinical aspect. In: Kaminishi M, Takubo K, Mafune K, editors. The diversity of gastric carcinoma. Springer; 2005. p. 29-47.
13. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008;38: 259-67.
14. Isajevs S, Liepniece-Karele I, Janciauskas D, Moisejevs G, Funka K, Kikuste I, et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol 2014;26: 510-3.
15. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20: 1161-81.
16. Leja M, Kupcinskas L, Funka K, Sudraba A, Jonaitis L, Ivanauskas A, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 2009;54: 2377-84.
17. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res 1995;86: 1210-5.
18. Kikuchi S, Kato M, Katsuyama T, Tominaga S, Asaka M. Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter 2006;11: 147-51.
19. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999;44: 693-7.
20. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, et al. The serum pepsinogen test as a predictor of gastric cancer: The Hisayama study. Am J Epidemiol 2006;163: 629-37.
21. Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: Outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2008;17: 838-45.
22. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: A prospective endoscopic cohort study. Gut 2005;54: 764-8.
23. Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010;55: 3132-7.
24. Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009;12: 158-63.
25. Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: Outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008;17: 838-45.
26. Kang JM, Kim N, Yoo JY, Park YS, Lee DH, Kim HY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008;13: 146-56.
27. Miki K, Fujishiro M. Cautious comparison between east and west is necessary in terms of the serum pepsinogen test. Dig Endosc 2009;21: 134-5.
28. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-"ABC method". Proc Jpn Acad Ser B Phys Biol Sci 2011;87: 405-14.
29. Formichella L, Romberg L, Bolz C, Vieth M, Geppert M, Gottner G, et al. A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infection. Clin vaccine Immunol : CVI 2013;20: 1703-10.
30. Michel A, Waterboer T, Kist M, Pawlita M. Helicobacter pylori multiplex serology. Helicobacter 2009;14: 525-35.
31. Gao L, Weck MN, Nieters A, Brenner H. Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: Enhanced elimination of the infection during disease progression? Eur J Cancer 2009;45: 2860-6.
32. Pan KF, Formichella L, Zhang L, Zhang Y, Ma JL, Li ZX, et al. Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population. Int J Cancer 2014;134: 2118-25.
33. Epplein M, ZhengW, Xiang YB, Peek Jr. RM, Li H, Correa P, et al. Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev 2012;21: 2185-92.
34. Song H, Michel A, Nyren O, Ekstrom AM, Pawlita M, YeW. A CagA-independent cluster of antigens related to the risk of noncardia gastric cancer: Associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serology. Int J Cancer 2014;134: 2942-50.
35. Agreus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47: 136-47.
36. Leja M, Kupcinskas L, Funka K, Sudraba A, Jonaitis L, Ivanauskas A, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 2011;56: 145-50.
37. Murphy G, Kamangar F, Dawsey SM, Stanczyk FZ, Weinstein SJ, Taylor PR, et al. The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas. J Natl Cancer Inst 2011;103: 1123-9.
38. Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology 2011;141: 837-45. e1-7.
39. Huang Z, Zhang X, Lu H, Wu L,Wang D, Zhang Q, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China. BMC Gastroenterol 2014;14: 74.
40. Zhang Y, Weck MN, Schottker B, Rothenbacher D, Brenner H. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: Evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev 2013;22: 821-6.
41. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93: 1054-61.
42. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 2008;100: 1432-8.
43. Lam KW, Lo SC. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics. Proteomics Clin Appl 2008;2: 219-28.
44. Huang Q, Huang Q, Chen W, Wang L, Lin W, Lin J, et al. Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J Cancer Res Clin Oncol 2008;134: 1219-27.
45. Ahn HS, Shin YS, Park PJ, Kang KN, Kim Y, Lee HJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer 2012;106: 733-9.
46. WuW, Chung MC. The gastric fluid proteome as a potential source of gastric cancer biomarkers. J proteomics 2013;90: 3-13.
47. Wu JY, Cheng CC,Wang JY,Wu DC, Hsieh JS, Lee SC, et al. Discovery of tumor markers for gastric cancer by proteomics. PLoS One 2014;9: E84158.
48. Zhang Y, Ren H, Jiang Y, Gao YF, Liu SY. Urinary metabonomics of stomach cancer assessed by rapid resolution liquid chromatography/time-of-fight mass spectrometry. Chin Med J 2013;126: 1930-3.
49. Cooke CL, Torres J, Solnick JV. Biomarkers of Helicobacter pylori-associated gastric cancer. Gut microbes 2013;4: 532-40.
50. Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: A meta-analysis. PLoS One 2012;7: E36275.
51. Link A, Kupcinskas J, Wex T, Malfertheiner P. Macro-role of microRNA in gastric cancer. Dig Dis 2012;30: 255-67.
52. Hishida A, Matsuo K, Goto Y, Hamajima N. Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions. World J Gastrointest Oncol 2010;2: 369-79.
53. Camargo MC, Mera R, Correa P, Peek Jr. RM, Fontham ET, Goodman KJ, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1674-87.
54. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer riskea meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15: 1920-8.
55. Peleteiro B, Lunet N, Carrilho C, Duraes C, Machado JC, La Vecchia C, et al. Association between cytokine gene polymorphisms and gastric precancerous lesions: Systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19: 762-76.
56. The Cancer Genome Atlas Research, Network Analysis Working Group. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517): 202-9.
57. Zhang L, Ren J, Pan K, Ma J, Li J, Shen L, et al. Detection of gastric carcinoma-associated MG7-Ag by serum immuno-PCR assay in a high-risk Chinese population, with implication for screening. Int J Cancer 2010;126: 469-73.
58. Zayakin P, Ancans G, Silina K, Meistere I, Kalnina Z, Andrejeva D, et al. Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer 2013;132: 137-47.
59. Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer 2013;108: 941-50.
60. Kuipers EJ. Review article: Exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 1999;13(Suppl. 1): 3-11.
61. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348: G3174.
62. Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol 2013;27: 933-47.
63. Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: A systematic review of cost-effectiveness studies. Helicobacter 2013;18: 325-37.
64. Moayyedi P. 2014. Feasibility and cost-effectiveness of population-based Helicobacter pylori eradication, In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. IARC Helicobacter pylori Working Group. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Ch 3.3, pp. 111-121. Available from: Http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
65. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: A community-based study of gastric cancer prevention. Gut 2013;62: 676-82.
66. Lee YC, Chiu HM, Chiang TH, Yen AM, Chiu SY, Chen SL, et al. Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions. BMJ open 2013;3: E003989.
67. Park JY, Forman D, Greenberg ER, Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: Are more trials needed? Curr Oncol reports 2013;15: 517-25.
68. Ford AC, Moayyedi P. Whom should we "test and treat" for Helicobacter pylori? BMJ 2014;348: G3320.
69. Ministry of Health, Labour and Welfare, Tokyo. [accessed 28.05.10]. Available from: Http://www.mhlw.go.jp/shingi/2004/04/s0427-2.html2004.
70. Health statistics in Japan. Tokyo: Ministry of Health, Labour and Welfare; 2007 [accessed 28.05.10]. Available from: Http://www.mhlw.go.jp/shingi/2004/04/s0427-2.html2007.
71. Ministry of Health, Labour and Welfare, Tokyo. [accessed 28.05.10]. Available from: Http://www.mhlw.go.jp/toukei/saikin/hw/c-hoken/06/r8.html2010.
72. Ministry of Health, Labour and Welfare, Tokyo. Report on regional public health services and health Promotion services 1999-2012. [accessed 01.04.13]. Available from: Http://www.e-stat.go.jp/SG1/estat/NewList.do? tid=0000010308842013.
73. Ministry of Health, Labour and Welfare, Tokyo. [accessed 29.07.14]. Available from: Http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa13/index.html2014.
74. Oshima A, Hirata N, Ubukata T, Umeda K, Fujimoto I. Evaluation of a mass screening program for stomach cancer with a case-control study design. Int J Cancer 1986;38: 829-33.
75. Fukao A, Tsubono Y, Tsuji I, HI S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: A population-based case-control study. Int J Cancer 1995;60: 45-8.
76. Mizoue T, Yoshimura T, Tokui N, Hoshiyama Y, Yatsuya H, Sakata K, et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer 2003;106: 103-7.
77. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S, et al. Gastric cancer screening and subsequent risk of gastric cancer: A large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006;118: 2315-21.
78. Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: Misunderstanding the role of mass screening. Gastric Cancer 2006;9: 315-9.
79. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132: 1272-6.
80. Fock KM. Review article: The epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 2014;40: 250-60.
81. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol 2014;49: 1-8.
82. Lee KS, Oh DK, Han MA, Lee HY, Jun JK, Choi KS, et al. Gastric cancer screening in Korea: Report on the national cancer screening program in 2008. Cancer Res Treat : Official J Korean Cancer Assoc 2011;43: 83-8.
83. Lee YY, Oh DK, Choi KS, Jung KW, Lee HY, Jun JK. The current status of gastric cancer screening in Korea: Report on the National Cancer Screening Programme, 2009. Asian Pac J Cancer Prev 2011;12: 3495-500.
84. Ministry of Health & Welfare. National Cancer Center. Cancer facts & figures 2013. Goyang, korea. [accessed 31.07.14]. Available from: Http://ncc.re.kr/english/infor/cff.jsp2014.
85. Choi KS, Jun JK, Lee HY, Park S, Jung KW, Han MA, et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea. Cancer Sci 2011;102: 1559-64.
86. Cho E, Kang MH, Choi KS, Suh M, Jun JK, Park EC. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev 2013;14: 2533-40.
87. You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993;53: 1317-21.
88. YouWC, Blot WJ, Zhang L, Kneller RW, Li JY, Jin ML, et al. Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiol Biomarkers Prev 1993;2: 113-7.
89. Lu YL, Lui LY,Wu Q, Lui WD, Li SJ, Cao CQ, et al. Comparison of two cancer screening schemes in a high-risk population. Chin J Oncol 2012;35: 394-7.
90. Guideline for upper gastroenterological cancer screening. China: Expert Panel: Ministry of Health; 2014. 2014-8-4. Available from: Http://onco.kz/node/142014.
91. Annual report of upper gastroenterological cancer screening 2012/2013. China: Expert Panel: Ministry of Health; 2014.
92. You W. 2014. Current gastric cancer prevention strategies in Linqu County, a high-risk area in Shandong Provence, China, In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. IARC Helicobacter pylori Working Group. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Ch 4.1., pp. 143-146. Available from: Http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
93. Torres J, Correa P, Ferreccio C, Hernandez-Suarez G, Herrero R, Cavazza-Porro M, et al. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. Cancer Causes Control 2013; 24: 249-56.
94. Pisani P, Oliver WE, Parkin DM, Alvarez N, Vivas J. Case-control study of gastric cancer screening in Venezuela. Br J Cancer 1994;69: 1102-5.
95. Rosero-Bixby L, Sierra R. X-ray screening seems to reduce gastric cancer mortality by half in a community-controlled trial in Costa Rica. Br J Cancer 2007;97: 837-43.
96. Malfertheiner P, Selgrad M. Gastric cancer screening in conjunction with colorectal cancer screening in Europe (GACSE). Clinical study Protocol, Version 1. 2013.
97. Leja M. 2014. The regional status of current or planned gastric cancer prevention strategies in Europe, In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. IARC Helicobacter pylori Working Group. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Ch 1.5., pp. 44-54. Available from: Http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
98. Leja M. Herrero R. Park J.Y. Plummer M. 2014. Multicentric randomized study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality (Gastric cancer prevention study by predicting atrophic gastritis; GISTAR), In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. IARC Helicobacter pylori Working Group. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), Ch 4.2., pp. 1474-1153. Available from: Http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
99. Kazakhstan Research Institute of Oncology and Radiology. Screening. [accessed 03.08.14]. Available from: Http://onco. kz/node/142014.
100. Lee YC, Wu HM, Chen TH, Liu TY, Chiu HM, Chang CC, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006;11: 418-24.